An interventional study of Exercise Intervention in Prostate Cancer Metastatic and Prostate Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — 12 open to participants now, 18 under way, none of them phase 3. Prostatic Neoplasms · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Among the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, this one is the 41st largest by planned enrollment of the 72 interventional ones that give a count, is one of 6 that started in 2025, is one of 15 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 70th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →12 of the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins are open now, in 1 country. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 38 · Phase 3 1
First in 2002; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 25 across the 72 interventional studies, 61 across the 5 observational. Of the 55 that completed or were terminated, 35 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is the lead sponsor of 582 studies on the registry; 71 are open to participants now.
Of its 114 completed or terminated interventional studies of FDA-regulated products, 68 (60%) have results posted.
5 of the studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059118Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDifluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | 2027-01-04 |
| NCT06826924Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer | 2027-06-03 |
| NCT04363164Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSequential Testosterone and Enzalutamide Prevents Unfavorable Progression | 2027-07 |
| NCT06138067Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPatient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients | 2027-09 |
| NCT07209176Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhysician- and Patient-based Barriers to NGS Testing | 2027-09-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 78 studies in Prostatic Neoplasms by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer. The primary objective is to determine if an exercise intervention decreases CTCs in men with advanced prostate cancer. Participants will have baseline screening assessments, followed by 12 weeks of exercise intervention, and then follow-up assessments 12 weeks after the end of the exercise intervention.
This is a pilot single arm prospective study of personalized exercise training in men with metastatic castration resistant prostate cancer who are being treated with or without oral anti-androgens. The primary objective is to determine if combination of resistance and aerobic exercises lowers CTCs in men with mCRPC. Researchers will assess the rate of conversion from CTC positive to CTC negative in participants at the end of the 12 week exercise intervention. The study will enroll 20 participants onto the trial with the goal of at least 10 participants having blood drawn at both baseline and 12 weeks and completed at least 75% of the prescribed exercise sessions. Participants will undergo follow-up assessments at the end of the 12 week exercise intervention and the study team will monitor participant records for 365 days after the study completion for vital status.
The criteria were revised on the registry on Oct 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be prescribed an exercise program after completing assessments at baseline. Participants will adhere to the prescribed exercise intervention for 12 weeks and log activity in a physical activity diary. Participants will return to clinic on Week 5 and Week 9 for assessments and adjustment to their exercise prescription as needed.
Behavioral: Exercise Intervention
12 weeks of prescribed exercise intervention.
Number of participants with negative CTC count
Number of participants with negative CTC count at 12 weeks compared to the baseline
Time frame: Baseline, 12 weeks
Number of participants with change in cell free DNA levels
Number of participants with change in cell free DNA levels from baseline to 12 weeks
Time frame: Baseline, 12 weeks
Number of participants with change in Cell free RNA levels
Number of participants with change in cell free RNA levels from baseline to 12 weeks
Time frame: Baseline, 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Mar 2029, 40 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 40 months is close to that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins →